Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities?

被引：26

作者：

Guba, W ^{[1
]}

Nettekoven, M ^{[1
]}

Püllmann, B ^{[1
]}

Riemer, C ^{[1
]}

Schmitt, S ^{[1
]}

机构：

[1] F Hoffmann La Roche & Co Ltd, Pharmaceut Res Basel, Discovery Chem, Lead Generat, CH-4070 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 12期

关键词：

adenosine amination; combinatorial chemistry; H-bond donor/acceptor strength triazolopyridine derivatives;

D O I：

10.1016/j.bmcl.2004.03.104

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis of an array of 8-amino-2-aryl-[1,2,4]triazolo[1,5-a]pyridine-6-carboxyl amide derivatives is described for the first time. A subset of 20 derivatives were compared to their isomeric 5-amino-2-aryl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxyl amide counterparts with regard to their potential to inhibit the human adenosine 2a (hA2a) receptor and their selectivity against the human adenosine 1 (hA1) receptor. Based on the analysis of H-bond donor/acceptor capabilities of the isomeric triazolopyridine pairs it can be concluded that the H-bond donor strength of the free amino functionality is the main determinant for hA2a inhibitory activity and hA1 selectivity. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：3307 / 3312

页数：6

共 15 条

[1] Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A(2A) adenosine antagonists [J].